CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Sells $93,559.73 in Stock

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 850,543 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $0.11, for a total value of $93,559.73. Following the completion of the sale, the insider now owns 20,533,366 shares in the company, valued at approximately $2,258,670.26. The trade was a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

CERo Therapeutics Stock Down 18.1 %

Shares of NASDAQ CERO traded down $0.02 during mid-day trading on Tuesday, hitting $0.09. The company had a trading volume of 16,480,674 shares, compared to its average volume of 20,468,281. CERo Therapeutics Holdings, Inc. has a 1-year low of $0.06 and a 1-year high of $12.80. The business’s 50-day simple moving average is $0.13 and its 200 day simple moving average is $0.23.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.